Cervical cancer

Cervical cancer, which is caused in nearly 100% of cases by a sexually transmitted human papillomavirus infection, can be prevented through HPV vaccination and screening.

Our missions

  • Monitoring epidemiological trends in cervical cancer

  • Evaluating the national organized cervical cancer screening program

  • Monitoring vaccination coverage for human papillomavirus infections

The disease

A cancer caused by the sexually transmitted HPV virus

Each year, nearly 3,000 women develop cervical cancer, and 1,000 women die from it.

In the vast majority of cases, cervical cancer is caused by a persistent infection with a high-risk human papillomavirus (HPV), a very common infection transmitted through sexual contact.

There are 12 HPV genotypes (known as high-risk) for which carcinogenesis has been established, and a 13th genotype considered a probable carcinogen. The genotypes most frequently associated with cervical cancer are HPV 16 and 18.

A persistent infection with high-risk HPV is a necessary but not sufficient condition for the development of cervical cancer. Other risk factors may act in conjunction with HPV: tobacco use, HIV infection, long-term use of oral contraceptives, and having had multiple pregnancies.

A Preventable Cancer

Cervical cancer can be prevented through two complementary interventions: HPV vaccination (primary prevention) and screening, which allows for the detection of precancerous lesions and their treatment before they develop into cancer (secondary prevention).

Key Statistics on Cervical Cancer

Infographie concernant le cancer du col de l’utérus

Key figures provided by the agency and its partners:

(Francim Cancer Registry Network, Hospices Civils de Lyon, National Cancer Institute, Regional Cancer Screening Coordination Centers)

Incidence

Mortality

Survival

Prevalence
(all cases)

Prevention: vaccination and screening

3,159 new cases per year

1,117 deaths per year

63% at 5 years

11,000 cases diagnosed in the last 5 years and still alive

33% of 16-year-old girls vaccinated with the HPV vaccine

France as a whole,
2020

58.8% of women aged 25–65 screened over 3 years

Metropolitan France,
2023

Metropolitan France,
2018

Metropolitan registry area, diagnosed cases,
2010–2015

Metropolitan France,
2017

All of France, 2018–2020